Takashi Kangas
YOU?
Author Swipe
View article: Early exposure to frequent microbial infections prevents both spontaneous and immune checkpoint inhibitor-induced autoimmune diabetes 4408
Early exposure to frequent microbial infections prevents both spontaneous and immune checkpoint inhibitor-induced autoimmune diabetes 4408 Open
Description It has been difficult to study contextually how infections may trigger or prevent autoimmune diabetes because diabetes mouse models are kept in specific pathogen-free (SPF) environments, which do not accurately correlate to an …
View article: 1327 Novel GCN2 modulator HC-7366 decreases pulmonary metastases and reduces myeloid-derived suppressor cells
1327 Novel GCN2 modulator HC-7366 decreases pulmonary metastases and reduces myeloid-derived suppressor cells Open
Background General controlled nonderepressible 2 (GCN2) is a central kinase in the integrated stress response (ISR) that responds to amino acid deprivation. Cancer cells can utilize the ISR for survival, but prolonged or hyperactivation of…
View article: 884 PERK inhibitor HC-5404 demonstrates immune-activation and anti-tumor efficacy in combination with anti-PD1 immune checkpoint inhibitor antibody
884 PERK inhibitor HC-5404 demonstrates immune-activation and anti-tumor efficacy in combination with anti-PD1 immune checkpoint inhibitor antibody Open
Background Protein kinase R-like endoplasmic reticulum kinase (PERK) is part of the unfolded protein response that facilitates cellular adaptation to ER stress. PERK is activated in cancer cells by accumulation of misfolded proteins in the…
View article: Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies
Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies Open
Imprime PGG (Imprime) is in late-stage clinical development as a combinatorial agent with several therapeutic modalities. Here we present pre-clinical mechanistic data supportive of Imprime, a soluble yeast β-1,3/1,6-glucan pathogen-associ…
View article: Imprime PGG, an innate immunomodulator for cancer immunotherapy has the potential to modulate macrophages in the tumor and the spleen to an anti-tumor M1-like phenotype
Imprime PGG, an innate immunomodulator for cancer immunotherapy has the potential to modulate macrophages in the tumor and the spleen to an anti-tumor M1-like phenotype Open
Meeting abstracts Imprime PGG (Imprime) in combination with anti-VEGF monoclonal antibody, bevacizumab has shown promising clinical efficacy in randomized Phase II clinical trials in non-small cell lung cancer (NSCLC) patients. Imprime, a …